GZMB Antibodies

Granzyme B (GZMB) is a serine protease found in the granules of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, playing a central role in inducing apoptosis in target cells. Upon release into the target cell, GZMB cleaves various substrates, leading to programmed cell death through both caspase-dependent and caspase-independent pathways. GZMB antibodies are essential for detecting, quantifying, and studying the function of this protease in immune responses, apoptosis, and immune-related diseases.

Content on GZMB Antibody

The GZMB antibody is highly specific to Granzyme B, a protease that contributes to immune-mediated cytotoxicity. It is a critical component in the immune system’s ability to eliminate virus-infected and tumor cells. GZMB initiates apoptosis by cleaving caspases and other cellular proteins, and its activity is tightly regulated during immune responses to prevent collateral tissue damage. GZMB antibodies are available as polyclonal and monoclonal forms, each designed to target specific epitopes of the GZMB protein.

Application of GZMB Antibody

• Immunohistochemistry (IHC): GZMB antibodies allow for the localization of Granzyme B in tissue sections, providing spatial information on GZMB-expressing cells in immune responses. In cancer research, IHC with GZMB antibodies can be used to determine the infiltration of cytotoxic lymphocytes into tumor tissues, which is often linked to the immune response against tumors.
• Autoimmune Disease Studies: GZMB plays a role in autoimmune diseases where excessive or dysregulated apoptosis leads to tissue damage. GZMB antibodies help in studying how the protease contributes to the destruction of self-cells, providing insights into the mechanisms underlying autoimmune diseases such as rheumatoid arthritis or lupus.
• Infection and Vaccine Research: GZMB antibodies are used to study the immune response to viral and bacterial infections, where CTLs and NK cells are key players in eliminating infected cells. Understanding GZMB dynamics can help evaluate vaccine efficacy by measuring the activity of cytotoxic lymphocytes post-vaccination.
• Cancer Immunotherapy Research: GZMB antibodies are critical in research on cancer immunotherapy, where enhancing the function of CTLs and NK cells is a primary goal. By evaluating GZMB expression and activity, researchers can determine the effectiveness of immunotherapies that aim to boost the cytotoxic function of immune cells against tumor cells.

GZMB antibodies are invaluable for exploring the mechanisms of immune-mediated apoptosis, cancer immunotherapy, and immune regulation in diseases, offering critical insights into immune system functionality and therapeutic interventions.